Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01010334 | Comparison of Standard of Care or Treatment on Protocol | terminated | N/A | 13 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00516750 | Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin | terminated | Phase 2 | 100 | Kyoto UniversityOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT01282333 |
| Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer |
| terminated |
| Phase 1 |
| 44 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 2, 2013 |
| clinicaltrials |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | terminated | Early Phase 1 | 3 | University Hospital, BordeauxOTHER | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00087295 | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium | terminated | Phase 2 | 6 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 2, 2012 | clinicaltrials |
| NCT01551407 | Detection of Bladder Tumors After 30 Min Instillation of Hexvix | terminated | Phase 2 | 38 | PhotocureINDUSTRY | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00042887 | Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | terminated | Phase 3 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00147238 | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast | terminated | N/A | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00237575 | Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer | terminated | Phase 3 | 100 | University of KentuckyOTHER | 1 | May 23, 2012 | clinicaltrials |
| NCT00003824 | S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer | terminated | Phase 3 | 114 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 9, 2012 | clinicaltrials |
| NCT00003640 | Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 73 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 6, 2012 | clinicaltrials |
| NCT00003642 | Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 43 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Mar 6, 2012 | clinicaltrials |
| NCT01215266 | Sorafenib in Urothelium Cancer of Bladder | terminated | Phase 2 | 98 | Association of Urologic Oncology (AUO)OTHER | 0 | Sep 8, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00191477 | Instillation of Gemcitabine in Patients With Superficial Bladder Cancer | terminated | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2009 | clinicaltrials |
| NCT00216814 | Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors | terminated | — | 220 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Apr 22, 2008 | clinicaltrials |
| NCT00249301 | A Study of MLN8054 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 63 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 1, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2013source: clinicaltrials